Company Summary - ImmuPharma PLC (LSE:IMM)
78.50p
0.50p
(0.64%)
FTSE AIM All Share Pharmaceuticals & BiotechnologyMarket cap: £64.003m
NEW Explore our new and improved report for ImmuPharma PLC >>
Gain access to various premium features such as detailed information on financial reports, broker forecasts, directors and shareholders information.
Summary
Drug discovery and development company
| Financials - Interim (30/9/2011) | ||
|---|---|---|
| Turnover | £m | 0 |
| Pre-tax Profit | £m | -2.11 |
| EPS | p | -2.59 |
| DPS | p | 0.00 |
| Director | Board Role |
|---|---|
| Richard Warr | Chairman |
| Dimitri Dimitriou | Chief Executive |
Products Brands & Subsidiaries
Products & Brands
There are no products for this company.
Subsidiaries
ImmuPharma (France) SA; ImmuPharma AG; ImmuPharma (UK) Ltd; Ureka SARL
Broker Sentiment (2 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| Director's Dealings | 24/01/2012 |
| Notification of Major Interest in Sh... | 08/11/2011 |
| LupuzorT granted approval to star... | 03/11/2011 |